title: Atypical neuroleptics and diabetes.
abstract: Since a few years, an increasing number of cases of atypical neuroleptic-associated diabetes are reported in the literature. But few are dedicated to diabetologists. We report here two cases of patients with a severe deterioration of preexisting diabetes, with clozapine for the first case report and olanzapine for the second one. We also make a literature review and discuss the possible mechanisms involved in this atypical neuroleptic-associated diabetes. We recommend a thigh follow-up of weight, glycemic and lipidic parameters during psychotic patients treatment with atypical neuroleptics, in order to prevent or rapidly treat the metabolic complications described in the literature.
authors.affiliation: Service de Nutrition, Maladies métaboliques, Endocrinologie, Hôpital de Sainte Marguerite, Marseille, France. bvialettes@mail.ap-hm.fr
authors.forename: S
authors.initials: S
authors.lastname: Béliard
authors.forename: R
authors.initials: R
authors.lastname: Valero
authors.forename: B
authors.initials: B
authors.lastname: Vialettes
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D003024:Clozapine / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced*; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D012306:Risk
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D003024:Clozapine; D000077152:Olanzapine